TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer

NCT ID: NCT04471480

Last Updated: 2020-07-15

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-01
• Study Completion Date: 2023-08-31

Brief Summary

A Controlled Clinical Study of TC/PD-1 Inhibitors Combined With anlotinib as First-line Treatment for Advanced ESCC

Detailed Description

The incidence rate of esophageal cancer is high in China and mainly squamous cell carcinoma. In recent years, although the level of surgery, radiotherapy and chemotherapy of esophageal cancer has improved, and studies have confirmed the role of anlotinib and PD-1 mAb in the posterior line treatment of esophageal squamous cell carcinoma, the prognosis of esophageal cancer is still not ideal. How to expand the clinical benefits of immunotherapy in esophageal cancer has become a research hotspot. Recent studies have shown that PD-1 mAb combined with other therapies with different mechanisms can improve the efficacy of immunotherapy. In the impawer150 study, platinum containing dual drug chemotherapy plus anti angiogenesis therapy combined with immunotherapy showed statistically and clinically significant PFS benefits in the first-line treatment of advanced non-small-cell lung cancer, which provides a new choice for the first-line treatment of advanced non-small-cell lung cancer. So far, there is no report on the first-line treatment of advanced esophageal squamous cell carcinoma with platinum containing dual drug chemotherapy plus anti angiogenesis drugs combined with immunotherapy. The purpose of this study is to evaluate the efficacy of cisplatin plus cisplatin in the treatment of advanced esophageal cancer.

Conditions

ESCC

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

group A，TCCA

paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +anlotinib 10mg, PO, d1-14, q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab plus anlotinib for maintenance therapy until PD or intolerable toxicity

Group Type: EXPERIMENTAL

TC/PD-1 inhibitor/anlotinib

Intervention Type: DRUG

chemotherapy and immunotherapy plus antiangiogenic therapy

group B，TCC

paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab for maintenance therapy until PD or intolerable toxicity

Group Type: EXPERIMENTAL

TC/PD-1 inhibitor/anlotinib

Intervention Type: DRUG

chemotherapy and immunotherapy plus antiangiogenic therapy

group C，TC

paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w

Group Type: OTHER

TC/PD-1 inhibitor/anlotinib

Intervention Type: DRUG

chemotherapy and immunotherapy plus antiangiogenic therapy

Interventions

TC/PD-1 inhibitor/anlotinib

chemotherapy and immunotherapy plus antiangiogenic therapy

Intervention Type: DRUG

Other Intervention Names

TC/PD-1 inhibitor

Eligibility Criteria

Inclusion Criteria

1. Patients volunteered to participate in the study and signed the informed consent;

2. Age 18-75, both male and female;

3. Histologically or cytologically confirmed advanced or metastatic (stage IIIB, III C or IV) ESCC .

4. At least one measurable lesion according to RECIST 1.1,which should not be treated locally, such as radiotherapy.

5. ECOG PS 0-1- Page 3 of 5 [DRAFT] -

6. Expected survival ≥ 3 months

7. Patients who never received systemic therapy in the past, including radiotherapy ,chemotherapy, targeted therapy and immunotherapy , or patients who relapsed more than 6 months after adjuvant chemotherapy.

8. The main organ functions accorded with the following criteria within 7 days before treatment:

(1)Blood routine examination ( without blood transfusion in 14 days): hemoglobin (HB) ≥ 90 g/L; neutrophil absolute value (ANC) ≥ 1.5 *109/L; platelet (PLT) ≥80 *109/L.

(2) Biochemical tests should meet the following criteria: 1) total bilirubin (TBIL) ≤1.5 times of upper limit of normal (ULN); 2) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 *ULN, if accompanied by liver metastasis, ALT and AST ≤ 5* ULN; 3) serum creatinine (Cr) ≤ 1.5* ULN or creatinine clearance rate (CCr) ≥ 60 ml/min;4) Serum albumin (≥35g/L). (3) Doppler echocardiography: left ventricular ejection fraction (LVEF) ≥the low limit of normal value (50%).

9 Tissue samples should be provided for biomarker analysis (such as PD-L1 ) Patients who could not provide new tissues could provide 5-8 paraffin sections of 3-5 μm by archival preservation.

Exclusion Criteria

1. Severe allergic reactions to humanized antibodies or fusion proteins in the past

2. known to have hypersensitivity to any component contained in Endostar or antibody preparations;

3. Diagnosed of immunodeficiency or received systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 14 days before the study, allowing physiological doses of glucocorticoids (≤10mg/day prednisone or equivalent);

4. Patients with active, known or suspected autoimmune diseases. Patients with type I diabetes, hypothyroidism requiring hormone replacement therapy, skin disorders requiring no systemic treatment(such as vitiligo, psoriasis or alopecia). Patients who would not triggers can be included.

5. Serious heart disease, include congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina pectoris, myocardial infarction, and severe valvular disease.

6. Patients treated targeted drugs such as bevacizumab, sunitinib, sorafenib, imatinib, famitinib, regiffenil, apatinib and anlotinib

7. Patients recieved systemic antineoplastic therapy, including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or mitomycin C within 6 weeks before the grouping),recieved over-extended-field radiotherapy (EF-RT) within 4 weeks before the grouping or limited-field radiotherapy to evaluate the tumor lesions within 2 weeks before the grouping

8. Positive hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus antibody (HCV Ab), indicating acute or chronic infection.

9. Patients with active pulmonary tuberculosis (TB) infection judged by chest X-ray examination, sputum examination and clinical physical examination. Patients with active pulmonary tuberculosis infection in the previous year should be excluded even if they have been treated; Patients with active pulmonary tuberculosis infection more than a year ago should also be excluded unless the course and type of antituberculosis treatment previously were appropriate.

10. Patients with brain metastases with symptoms or symptoms controlling less than 2 months

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dong Wang

OTHER

Sponsor Role: lead

Responsible Party

Dong Wang

Head of Oncology

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Daping Hospital, Third Military Medical University

Chongqing, Chongqing Municipality, China

Countries

China

Central Contacts

Dong Wang, PH.D

Role: CONTACT

dongwang64@hotmail.com

86-23-68757181

Dong Wang, PH.D

Role: CONTACT

dongwang64@hotmail.com

13678428206

Facility Contacts

Dong Wang, PH.D.

Role: primary

dongwang64@hotmail.com

86-23-68757151

References

Xu M, Pu Y, Jiang Y, Liu Y, Feng Y, Zhao X, Li M. Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma. Sci Rep. 2025 Jul 1;15(1):22275. doi: 10.1038/s41598-025-06625-2.

Reference Type: DERIVED

PMID: 40595001 (View on PubMed)

Other Identifiers

TCAC-ESCC-01

Identifier Type: -

Identifier Source: org_study_id